OrSense Ltd. (Nes Ziona, Israel) announced it has received FDA approval for the NBM-200MP non-invasive and low signal oximetry sensor. We previously reported on this device last year. Pulse oximetry is widely used in hospitals to monitor patients’ blood oxygen levels, but the technology is plagued with false alarms and gives erroneous results when perfusion is low. OrSense has developed a proprietary technique called occlusion spectroscopy in which pressure is applied by a sensor around the finger, temporarily occluding the blood flow in the finger. Then an optical signal is measured with a high signal-to-noise ratio that is wholly blood specific. This allows for more accurate oximetry measurements during states of low perfusion. In addition to oxygen, the device also measures glucose, hemoglobin and pulse rate.
Product Animation:
Press release: OrSense Receives U.S. FDA Approval for NMB-200MP Non-Invasive Oximetry Monitoring System…
Product Page: OrSense…
